RxDoctor Payments Data

Lee Hartner, MD

Hematology & Oncology · Philadelphia, PANPI 1770577116

Payments from drug & device makers

$495,246in general payments, 2019–2025

Across 59 payments — averaging $8393.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$236K
  • PTC Therapeutics, Inc.$198K
  • Karyopharm Therapeutics Inc.$32K
  • Springworks Therapeutics, Inc.$16K
  • Eli Lilly$14K
  • Servier Pharmaceuticals LLC$159
  • plus $65 from 2 others
$1,552in research payments, 2019–2025

Across 12 payments — averaging $129.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • PTC Therapeutics, Inc.$2K

What the payments were for

  • Education$224100%

General payments by program year

21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$495,246 in reported general payments places this provider in the 85th percentile of 682 hematology & oncology providers in Pennsylvania.

See all hematology & oncology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$227,847
Medicare patients
562
Services billed
2,626

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VotrientPazopanib Hcl20$295,979
BrukinsaZanubrutinib14$191,131
CalquenceAcalabrutinib Maleate11$158,140
NubeqaDarolutamide11$146,751
Imatinib Mesylate29$52,574
EliquisApixaban15$13,588
XareltoRivaroxaban14$10,241
Oxycodone Hcl45$788
Dexamethasone39$698
Hydroxyurea19$656
Prochlorperazine Maleate44$333
Gabapentin20$327
ValacyclovirValacyclovir Hcl12$151
Ondansetron Hcl37$149
Prednisone24$37

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence$43$158,14011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 682 hematology & oncology providers in Pennsylvania.

Other hematology & oncology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →